Accession Therapeutics appoints Nicklasson as chairman

OXFORD, UK - Accession Therapeutics Limited announced the appointment of two new Non-Executive members to its board. Martin Nicklasson, with nearly four decades of experience in the biopharmaceutical industry, becomes the Non-Executive Chairman. He was previously the Chairman of Zealand Pharma and Kymab, which was acquired by Sanofi for $1.45 billion in 2021.

Nicklasson has held board positions at Basilea Pharmaceutica and Nykode Therapeutics, previously served as CEO of Biovitum and SOBI, and worked in executive roles at Astra and AstraZeneca.

Pierre d’Epenoux, bringing over three decades of expertise in operational management, strategic planning, and business development, is appointed as Non-Executive Director. His most recent role was as CEO of ImCheck Therapeutics, an immuno-oncology company acquired by Ipsen for up to $1.2 billion in December 2025. D’Epenoux has held senior corporate development positions at Sanofi, Baxter Healthcare, and Merck KGaA. He currently chairs Elkedonia, a biotech company focused on neurology and depression.

Nick Cross, co-founder of Accession Therapeutics alongside CEO Bent Jakobsen in 2021, relinquishes the position of Executive Chairman but remains a director on the board. Accession Therapeutics is a clinical-stage biopharmaceutical company developing cancer immunotherapies.